APA (7th ed.) Citation

S, M., IN, B., EF, M., R, F., Y, T., KC, K., . . . C, L. (2026). Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study. Arthritis & rheumatology (Hoboken, N.J.), 78(6), 1258. https://doi.org/10.1002/art.70041

Chicago Style (17th ed.) Citation

S, Manzi, et al. "Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study." Arthritis & Rheumatology (Hoboken, N.J.) 78, no. 6 (2026): 1258. https://doi.org/10.1002/art.70041.

MLA (9th ed.) Citation

S, Manzi, et al. "Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study." Arthritis & Rheumatology (Hoboken, N.J.), vol. 78, no. 6, 2026, p. 1258, https://doi.org/10.1002/art.70041.